Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592119 | 0.80 | CHRM2 (0.48) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2590190 | 0.80 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2592355 | 0.78 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2903136 | 0.77 | FAAH (0.49) | FAAHGPR119 | |
| SCHEMBL2587471 | 0.76 | GPR119 (0.46) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2583990 | 0.75 | GPR119 (0.48) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL8207978 | 0.74 | POLB (0.48) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2584550 | 0.74 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2591601 | 0.74 | OPRM1 (0.49) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL2584714 | 0.74 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2563780-B1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11(BETA)-HSD1 | UNIV EDINBURGH (GB) | 2015-05-06 | — | — | EP | disclosed |
| EP-2563780-B1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11(BETA)-HSD1 | UNIV EDINBURGH (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| EP-2563780-A1 | 3, 3 -DISUBSTITUTED- ( 8 - AZA - BICYCLO [3.2.1]OCT- 8 - YL) -[5- (1H - PYRAZOL - 4 -YL) -THIOPHEN-3 -YL]METHANONES AS INHIBITORS OF 11 (BETA) -HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135276-A1 | 3, 3 -DISUBSTITUTED- ( 8 - AZA - BICYCLO [3.2.1] OCT- 8 - YL) -[5- (1H - PYRAZOL - 4 -YL) -THIOPHEN-3 -YL] METHANONES AS INHIBITORS OF 11 (BETA) -HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | HSD11B1, HSD3B1, HSD17B1 | CHRM2 2746/4885CHRM1 1841/4885CHRM3 2940/4885 |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | HSD11B1, HSD3B1, HSD17B1 | CHRM2 2746/4885CHRM1 1841/4885CHRM3 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.